JAB-3312 is a potent allosteric inhibitor of SHP2 with an IC50 of 1.9 nM and a Kd of 0.37 nM. It is a potential anticancer agent and can be used in cancer research.

D34-919 is potent inhibitor of the ALDH1A3-PKM2 interaction, and prevents the ALDH1A3-mediated enhancement of PKM2 tetramerization. D34-919 mediated in vitro and in vivo treatment enhances and restores chemoradiotherapy-induced apoptosis and sensitivity in glioblastoma (GBM) cells.

JAB-3312 is a potent allosteric inhibitor of SHP2 with an IC50 of 1.9 nM and a Kd of 0.37 nM. It is a potential anticancer agent and can be used in cancer research.

D34-919 is potent inhibitor of the ALDH1A3-PKM2 interaction, and prevents the ALDH1A3-mediated enhancement of PKM2 tetramerization. D34-919 mediated in vitro and in vivo treatment enhances and restores chemoradiotherapy-induced apoptosis and sensitivity in glioblastoma (GBM) cells.

Culmerciclib (TQB3616) is a potent inhibitor of cyclin dependent kinase (CDK)4/6 and exhibits highly effective antineoplastic activity. TQB3616 exhibits significant synergistic antitumor activity in estrogen receptor (ER)-positive/HER2-negative or HER2-positive breast cancer when combined with endocrine therapy or Human Epidermal Growth Factor Receptor 2 (HER2) targeted therapy.

D34-919 is potent inhibitor of the ALDH1A3-PKM2 interaction, and prevents the ALDH1A3-mediated enhancement of PKM2 tetramerization. D34-919 mediated in vitro and in vivo treatment enhances and restores chemoradiotherapy-induced apoptosis and sensitivity in glioblastoma (GBM) cells.

D34-919 is potent inhibitor of the ALDH1A3-PKM2 interaction, and prevents the ALDH1A3-mediated enhancement of PKM2 tetramerization. D34-919 mediated in vitro and in vivo treatment enhances and restores chemoradiotherapy-induced apoptosis and sensitivity in glioblastoma (GBM) cells.

Culmerciclib (TQB3616) is a potent inhibitor of cyclin dependent kinase (CDK)4/6 and exhibits highly effective antineoplastic activity. TQB3616 exhibits significant synergistic antitumor activity in estrogen receptor (ER)-positive/HER2-negative or HER2-positive breast cancer when combined with endocrine therapy or Human Epidermal Growth Factor Receptor 2 (HER2) targeted therapy.

Culmerciclib (TQB3616) is a potent inhibitor of cyclin dependent kinase (CDK)4/6 and exhibits highly effective antineoplastic activity. TQB3616 exhibits significant synergistic antitumor activity in estrogen receptor (ER)-positive/HER2-negative or HER2-positive breast cancer when combined with endocrine therapy or Human Epidermal Growth Factor Receptor 2 (HER2) targeted therapy.

Culmerciclib (TQB3616) is a potent inhibitor of cyclin dependent kinase (CDK)4/6 and exhibits highly effective antineoplastic activity. TQB3616 exhibits significant synergistic antitumor activity in estrogen receptor (ER)-positive/HER2-negative or HER2-positive breast cancer when combined with endocrine therapy or Human Epidermal Growth Factor Receptor 2 (HER2) targeted therapy.